An update on the management of peripheral T-cell lymphoma and emerging treatment options

References

• SwerdlowSCampoEHarrisNWorld Health Organization Clas-sification of Tumours of Haematopoietic and Lymphoid tissues4th edLyonInternational Agency for Research on Cancer2008
   Google Scholar
• JaffeESHarrisNLSteinHVardimanJWWorld Health Organization Classification of Tumours: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid TissuesLyonIARC Press2001
   Google Scholar
• JaffeESPathobiology of peripheral T-cell lymphomasHematology Am Soc Hematol Educ Program200631732217124078
   PubMedGoogle Scholar
• AbouyabisANShenoyPJLechowiczMJFlowersCRIncidence and outcomes of the peripheral T-cell lymphoma subtypes in the United StatesLeuk Lymphoma200849112099210719021052
   PubMed Web of Science ®Google Scholar
• RudigerTWeisenburgerDDAndersonJRPeripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkins Lymphoma Classification ProjectAnn Oncol200213114014911863096
   PubMed Web of Science ®Google Scholar
• VoseJArmitageJWeisenburgerDInternational T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomesJ Clin Oncol200826254124413018626005
   PubMed Web of Science ®Google Scholar
• ten BergeRLde BruinPCOudejansJJALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecifiedHistopathology200343546246914636272
   PubMed Web of Science ®Google Scholar
• SavageKJHarrisNLVoseJMALK-anaplastic large-cell lym-phoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-cell Lymphoma ProjectBlood2008111125496550418385450
   PubMed Web of Science ®Google Scholar
• NelsonMHorsmanDEWeisenburgerDDCytogenetic abnormalities and clinical correlations in peripheral T-cell lymphomaBr J Haematol2008141446146918341637
   PubMed Web of Science ®Google Scholar
• ZettleARudigerTKonradMAGenomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterationsAm J Pathol200416451837184815111330
   PubMed Web of Science ®Google Scholar
• Martinez-DelgadoBCuadrosMHonradoEDifferential expression of NF-kappa B pathway genes among peripheral T-cell lymphomasLeukemia200519122254226316270046
   PubMed Web of Science ®Google Scholar
• PiccalugaPPAgostinelliCZinzaniPLExpression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specifiedLancet Oncol20056644015925824
   PubMed Web of Science ®Google Scholar
• StreubelBVinatzerUWillheimMRadererMChottANovel t(5;9) (q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphomaLeukemia200620231331816341044
   PubMed Web of Science ®Google Scholar
• PivaRAgnelliLPellegrinoEGene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasmsJ Clin Oncol20102891583159020159827
   PubMed Web of Science ®Google Scholar
• De LevalLGaulardPPathobiology and molecular profiling of peripheral T-cell lymphomasHematology Am Soc Hematol Educ Program200827227919074096
   PubMedGoogle Scholar
• GallaminiAStelitanoCCalviRPeripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical studyBlood200410372474247914645001
   PubMed Web of Science ®Google Scholar
• De LevalLGisselbrechtCGaulardPAdvances in the understanding and management of angioimmunoblastic T-cell lymphomaBr J Haematol2010148567368919961485
   PubMed Web of Science ®Google Scholar
• IqbalJWeisenburgerDDGreinerTCMolecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphomaBlood201011551026103619965671
   PubMed Web of Science ®Google Scholar
• PautierPDevidasADelmerAAngioimmunoblastic-like T-cell non Hodgkin’s lymphoma: outcome after chemotherapy in 33 patients and review of the literatureLeuk Lymphoma1999325–654555210048427
   PubMed Web of Science ®Google Scholar
• AdvaniRHorwitzSZelenetzAHorningSJAngioimmunoblastic T-cell lymphoma: treatment experience with cyclosporineLeuk Lymphoma200748352152517454592
   PubMed Web of Science ®Google Scholar
• GerlandoQBaberaVAmmatunaEFrancoVFlorenaAMMarianiGSuccessful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma combined with methotrexate and prednisoneHaematologica200085888088110942945
   PubMed Web of Science ®Google Scholar
• DoganANguLSNgSHCerviPLPathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomideLeukemia200519587387515744336
   PubMed Web of Science ®Google Scholar
• JolyBFrankelVBelhadjKRituximab in combination with CHOP regimen in T-cell angioimmunoblastic lymphoma (AITL-TL) rich in large B cells. Favourable results in four patients [Abstract]J Clin Oncol20042214S6694
   Google Scholar
• AmengualJERaphaelBGSustained, durable responses with alem-tuzumab in refractory angioimmunoblastic T-cell lymphomaLeuk Lymphoma20105171347135020572801
   PubMed Web of Science ®Google Scholar
• KyriakouCCanalsCGoldstoneAHigh-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome- Lymphoma Working Party of the European Group for Blood and Marrow TransplantationJ Clin Oncol200826221822418182664
   PubMed Web of Science ®Google Scholar
• KyriakouCCanalsCMFinkeJAllogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantationJ Clin Oncol200927243951395819620487
   PubMed Web of Science ®Google Scholar
• SteinHMasonDYGerdesJThe expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cellsBlood19856648488583876124
   PubMed Web of Science ®Google Scholar
• RimokhRMaguadJPBergerFA translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (‘Ki-1 lymphoma’)Br J Haematol198971131362917127
   PubMed Web of Science ®Google Scholar
• AminHMLaiRPathobiology of ALK+ anaplastic large-cell lymphomaBlood200711072259226717519389
   PubMed Web of Science ®Google Scholar
• BitterMAFranklinWALarsonRAMorphology of Ki-1 (CD30)-positive non-Hodgkin’s lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5) (p23;q35)Am J Surg Pathol19901443053162157342
   PubMed Web of Science ®Google Scholar
• SavageKJHarrisNLVoseJMALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma ProjectBlood2008111125496550418385450
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphomaThe Non-Hodgkin’s Lymphoma Classification ProjectBlood19978911390939189166827
   PubMed Web of Science ®Google Scholar
• FaliniBPileriSZinzaniPLALK+ lymphoma: clinicopathologic findings and outcomeBlood19999382697270610194450
   PubMed Web of Science ®Google Scholar
• JagasiaMMorganDGoodmanSHistology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplantLeuk Lymphoma200445112261226715512815
   PubMed Web of Science ®Google Scholar
• BlystadAKEnbladGKvaloySHigh-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomasBone Marrow Transplant200127771171611360110
   PubMed Web of Science ®Google Scholar
• KwakELBangY-JCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell-lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCMessaCPoglianiEMCrizotinib in Anaplastic Large-Cell LymphomaN Engl J Med2011364877577621345110
   PubMed Web of Science ®Google Scholar
• HarabuchiYImaiSWakashimaJNasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studiesCancer19967710213721498640683
   PubMed Web of Science ®Google Scholar
• HuangYde ReyniesAde LevalLGene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal typeBlood201011561226123719965620
   PubMed Web of Science ®Google Scholar
• MaHHQianLTPanHFTreatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphomaMed Oncol201027379880619685292
   PubMed Web of Science ®Google Scholar
• JaccardAGachardNMarinBEfficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 studyBlood201111761834183921123825
   PubMed Web of Science ®Google Scholar
• ProiettiFACarneiro-ProiettiABCatakan-SoaresBCMurphyELGlobal epidemiology of HTLV-1 infection and associated diseasesOncogene200524396058606816155612
   PubMed Web of Science ®Google Scholar
• ShimoyamaMDiagnostic criteria and classification of clinical subtypes of adult t-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984–1987)Br J Haematol19917934284371751370
   PubMed Web of Science ®Google Scholar
• SunSCYamaoakaSActivation of NF-kappa B by HTLV-1 and implications for cell transformationOncogene200524395952596416155602
   PubMed Web of Science ®Google Scholar
• RamosJCRuizPRatnerLIRF-4 and c-REL expression in antiviral-resistant adult T-cell leukemia/lymphomaBlood200710973060306817138822
   PubMed Web of Science ®Google Scholar
• OshiroATagawaHOhshimaKIdentification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphomaBlood2006107114500450716484591
   PubMed Web of Science ®Google Scholar
• IshitsukaKTamuraKTreatment of adult T-cell leukemia/lymphoma: past, present, and futureEur J Haematol200880318519618081707
   PubMed Web of Science ®Google Scholar
• TsukasakiKUtsunomiyaAFukudaHVCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia lymphoma: Japan Clinical Oncology Group Study JCOG9801J Clin Oncol200725345458546417968021
   PubMed Web of Science ®Google Scholar
• GillPSHarringtonWKaplanMHTreatment of adult T-cell leukemia/lymphoma with a combination if interferon alpha and zidovudineN Engl J Med199533226174417487760890
   PubMed Web of Science ®Google Scholar
• HermineOBouscaryDGessainABrief Report: Treatment of HTLV-1 associated adult T-cell leukemia-lymphoma with a combination of zidovudine and alpha-interferonN Engl J Med199533226174917517760891
   PubMed Web of Science ®Google Scholar
• HermineOAllardILevyVA prospective phase II clinical trial with the use of zidqvudine and alpha interferon in the acute and lymphomatous forms of adult T-cell leukemia/lymphomaHematol J20023627628212522449
   PubMedGoogle Scholar
• BazarbachiAPlumelleYRamosCMeta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypesJ Clin Oncol201028274177418320585095
   PubMed Web of Science ®Google Scholar
• PhillipsAAWillimRSavageDA multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patientsLeuk Lymphoma20095061039104219373596
   PubMed Web of Science ®Google Scholar
• FukushimaTMiyazakiYHondaSAllogeneic hematopoi-etic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphomaLeukemia200519582983415744352
   PubMed Web of Science ®Google Scholar
• ZettlAdeLeeuwRHaralambievaEMueller-HermelinkHKEnteropathy-type T-cell lymphomaAm J Clin Pathol2007127570170617511112
   PubMed Web of Science ®Google Scholar
• SieniawskiMAngamuthuNBoydKEvaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantationBlood2010115183664367020197551
   PubMed Web of Science ®Google Scholar
• TackGJVerbeekWHAl-TomaAEvaluation of Cladribine treatment in refractory celiac disease type IIWorld J Gastroenterol201117450651321274381
   PubMed Web of Science ®Google Scholar
• FalchookGSVegaFDangNHHepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatmentAnn Oncol20092061080108519237479
   PubMed Web of Science ®Google Scholar
• ZelenetzADAbramsonJSAdvaniRH NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas; Version 3.2011. Available from: http://www.nccn.org/. Accessed May 6, 2011.
   Google Scholar
• FisherRIGaynorERDahlbergSComparison of a standard regimen (CHOP) with three chemotherapy regimens for advanced non-Hodgkin’s lymphomaN Engl J Med199332814100210067680764
   PubMed Web of Science ®Google Scholar
• SchmitzNTrumperLZiepertMTreatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study GroupBlood2010116183418342520660290
   PubMed Web of Science ®Google Scholar
• SimonAPeoachMCasassusPUpfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphomas. Results of the randomized phase III trial GOELAMS-LTP95Br J Haematol2010151215916620738307
   PubMed Web of Science ®Google Scholar
• SungHJKimSJSeoHYProspective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional studyBr J Haematol20061341455316803566
   PubMed Web of Science ®Google Scholar
• KimJGSohnSKChaeYSCHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T-cell lymphomasCancer Chemother Pharmacol2006581353916308699
   PubMed Web of Science ®Google Scholar
• KimJGSohnSKChaeYSAlemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II studyCancer Chemother Pharmacol200760112913417406867
   PubMed Web of Science ®Google Scholar
• GallaminiAZajaGPattiCAlemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trialBlood200711072316232317581918
   PubMed Web of Science ®Google Scholar
• TakamatsuYSuzumiyaJUtsunomiyaATHP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II studyEur J Haematol201084539139720059527
   PubMed Web of Science ®Google Scholar
• Kluin-NelemansHCvan Marwijk KooyMLugtenburgPJIntensified alemtuzumab-CHOP therapy for peripheral T-cell lymphomaAnn Oncol20112271595160021212158
   PubMed Web of Science ®Google Scholar
• d’AmoreFJantunenERelanderTHematopoeitic stem cell transplantation in T-cell malignancies: who, when and how?Curr Hematol Malig Rep20094423624420425413
   PubMedGoogle Scholar
• RodriguezJCaballeroMDGutierrexAHigh-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experienceAnn Oncol200314121768177514630683
   PubMed Web of Science ®Google Scholar
• ReimerPRuedigerTGeissingerEAutologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter studyJ Clin Oncol200927110611319029417
   PubMed Web of Science ®Google Scholar
• CorradiniPDoderaAZallioFGraft versus lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced intensity conditioning followed by allogeneic transplantation of hematopoietic cellsJ Clin Oncol200422112172217615169805
   PubMed Web of Science ®Google Scholar
• Le GouillSMilpiedNBuzynAGraft versus lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie CellulaireJ Clin Oncol200826142264227118390969
   PubMed Web of Science ®Google Scholar
• O’ConnorOAHorwitzSHamlinPPhase II-I-II study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignanciesJ Clin Oncol200927264357436419652067
   PubMed Web of Science ®Google Scholar
• O’ConnorOAProBPinter-BrownLPralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL studyJ Clin Oncol20112991182118921245435
   PubMed Web of Science ®Google Scholar
• ZinzaniPLVenturiniFStefoniVGemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcomeAnn Oncol201021486086319887465
   PubMed Web of Science ®Google Scholar
• HorwitzSMulfordDPaulHClofarabine is active in peripheral T-cell lymphomas: results of the phase I portion of a phase I/II studyAnn Oncol200819Suppl 4iv157 (abstract #244).
   Google Scholar
• DeAngeloDJYuDJohnsonJLNelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lym-phoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19 801Blood2007109125136514217344466
   PubMed Web of Science ®Google Scholar
• CzuczmanMSPorcuPJohnsonJResults of a phase II study of 506U78 in CTCL and PTCLBlood2004104Suppl 1682a (abstract #2486).
   Google Scholar
• GandhiVKilpatrickJMPlunkettWA proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phophorylase inhibitor immucillin-H (BCX-1777, forodesine)Blood2005106134253426016131572
   PubMed Web of Science ®Google Scholar
• PiekarzRLFryeRPrinceHMPhase II trial of romidepsin in patients with peripheral T-cell lymphomaBlood2011117225827583421355097
   PubMed Web of Science ®Google Scholar
• GinaldiLDe MartinisMMatutesELevels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1HLeuk Res19982221851919593475
   PubMed Web of Science ®Google Scholar
• EnbladGHagbergHErlansonMA pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomasBlood200410382920292415070664
   PubMed Web of Science ®Google Scholar
• BartlettNLYounesACarabasiMHA phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignanciesBlood200811141848185418079362
   PubMed Web of Science ®Google Scholar
• YounesAForero-TorresABartlettNLObjective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin LymphomaAnn Oncol200819Suppl 4iv129iv130 (abstract #141).
   Google Scholar
• DangNHProBHagemeisterFBPhase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin’s lymphomaBr J Haematol2007136343944717233846
   PubMed Web of Science ®Google Scholar
• D’AmoreFRadfordJRelanderTPhase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T-cell lymphomaBr J Haematol2010150556557320629661
   PubMed Web of Science ®Google Scholar
• O’MahoneyJCMorrisJCMosesLPhase I trial of siplizumab in CD2-positive lymphoproliferative diseaseBlood2005106937a (abstract #3353).
   Web of Science ®Google Scholar
• DaviesFBazRLenalidomide mode of action: linking bench and clinical findingsBlood Rev2010Suppl 1S13S1921126632
   PubMed Web of Science ®Google Scholar
• DueckGChuaNPrasadAInterim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphomaCancer2010116194541454820572046
   PubMed Web of Science ®Google Scholar
• LeeJShuhCKangHJPhase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphomaAnn Oncol200819122079208318689866
   PubMed Web of Science ®Google Scholar
• MerciecaJMatutesEDeardenCMacLennanKCatovskyDThe role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtypeJ Clin Oncol19941212258825937989933
   PubMed Web of Science ®Google Scholar
• SallahSWanJYNguyenNPTreatment of refractory T-cell malignancies using gemcitabineBr J Haematol2001113118518711328299
   PubMed Web of Science ®Google Scholar
• ArkenauHTChongGCunninghamDGemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experienceHaematologica200792227127217296587
   PubMed Web of Science ®Google Scholar
• KimSJKimKKimBSAlemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective studyAnn Oncol200920239039219211502
   PubMed Web of Science ®Google Scholar
• CoiffierBProBPrinceHMFinal results from a pivotal, multicenter, international, open-label, phse 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapyASH Annual Meeting Abstracts2010116114
   Google Scholar